Clinical trial · Interventional
Feasibility and Clinically Application of Magnetic Resonance Fingerprinting
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): technician left institution
Summary
Brief summary (as posted)
This study will look at the feasibility of using magnetic resonance fingerprinting (MRF) in children, adolescents and young adults (AYA) with and without brain tumors. This study will also look at subjects with and without neurofibromatosis type 1(NF1), a genetic disorder that affects the growth of nervous system cells. Further, it will explore potential ways of using of MRF signal measurements in children, adolescents, and young adults with brain tumors, including tissue characterization, looking at whether the treatment was effective, and finding metastasized tumors of unknown origin (occult tumors). To explore the feasibility and potential applications of MRF, this study will recruit up to 80 subjects but will stop once 10 subjects have usable data in each of six groups.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Tumor | Brain Neoplasm | ALIAS | 0.90 |
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
| Neurofibromatosis Type 1 | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnetic Resonance Fingerprinting | Device | — | UNRESOLVED |
| Magnetic Resonance Imaging | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- type
- EXPERIMENTAL
- label
- NF1-associated Optic Pathway Glioma (OPG)
- description
- Patients with neurofibromatosis type 1 (NF1) associated OPG will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
- interventionNames
- Device: Magnetic Resonance Imaging
- Device: Magnetic Resonance Fingerprinting
- type
- EXPERIMENTAL
- label
- NF1 without brain tumor
- description
- Patients with NF1 without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
- interventionNames
- Device: Magnetic Resonance Imaging
- Device: Magnetic Resonance Fingerprinting
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects undergoing MRI evaluation of the brain * NF1 status will be determined by clinical exam or genetic testing * NF1-associated Optic Pathway Glioma (OPG) will be defined as radiographic evidence of glioma along the optic nerve, chiasm, tract or radiation in a child with NF1 * Untreated low grade gliomas will be imaging-defined gliomas that have not yet been exposed to radiation or systemic chemotherapy. Those exposed to therapy will have had radiation and/or systemic chemotherapy more than 1 month prior to scans Exclusion Criteria: * History of mental retardation unrelated to brain tumor * Presence of a genetic disorder other than NF1 that effects cognition or is associated with MR imaging abnormalities (e.g. tuberous sclerosis) * History of cerebrovascular accident (stroke) * Birth weight below five pounds, premature birth prior to 36 weeks of gestation, or ischemic episode at birth * Major psychiatric diagnosis prior to neuro-oncological diagnosis
References
Publications (0)
Data not yet available